It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The E1 enzyme Uba6 initiates signal transduction by activating ubiquitin and the ubiquitin-like protein FAT10 in a two-step process involving sequential catalysis of adenylation and thioester bond formation. To gain mechanistic insights into these processes, we determined the crystal structure of a human Uba6/ubiquitin complex. Two distinct architectures of the complex are observed: one in which Uba6 adopts an open conformation with the active site configured for catalysis of adenylation, and a second drastically different closed conformation in which the adenylation active site is disassembled and reconfigured for catalysis of thioester bond formation. Surprisingly, an inositol hexakisphosphate (InsP6) molecule binds to a previously unidentified allosteric site on Uba6. Our structural, biochemical, and biophysical data indicate that InsP6 allosterically inhibits Uba6 activity by altering interconversion of the open and closed conformations of Uba6 while also enhancing its stability. In addition to revealing the molecular mechanisms of catalysis by Uba6 and allosteric regulation of its activities, our structures provide a framework for developing Uba6-specific inhibitors and raise the possibility of allosteric regulation of other E1s by naturally occurring cellular metabolites.
Uba6 is an E1 enzyme that regulates numerous cellular processes by activating ubiquitin and FAT10 pathways. Here, the authors present crystal structures that illuminate Uba6 catalytic mechanisms and reveal inositol hexakisphosphate as a cofactor that modulates Uba6 activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Texas Health Science Center at San Antonio, Department of Biochemistry & Structural Biology, San Antonio, USA (GRID:grid.267309.9) (ISNI:0000 0001 0629 5880)
2 University of Texas Health Science Center at San Antonio, Department of Biochemistry & Structural Biology, San Antonio, USA (GRID:grid.267309.9) (ISNI:0000 0001 0629 5880); Beijing IPE Center for Clinical Laboratory CO, Department of Research & Development, Beijing, China (GRID:grid.267309.9)
3 Medical University of South Carolina, Department of Biochemistry & Molecular Biology and Hollings Cancer Center, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475)
4 Johns Hopkins University School of Medicine, Department of Pediatrics, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
5 University of South Alabama, Department of Biochemistry & Molecular Biology, Mobile, USA (GRID:grid.267153.4) (ISNI:0000 0000 9552 1255)
6 UbiQ Bio B.V., Amsterdam, The Netherlands (GRID:grid.267153.4)
7 University of Texas Health Science Center at San Antonio, Department of Biochemistry & Structural Biology, San Antonio, USA (GRID:grid.267309.9) (ISNI:0000 0001 0629 5880); Memorial Sloan Kettering Cancer Center, Human Oncology and Pathogenesis Program, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)